Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial.
Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)
